Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908824 | Leukemia Research | 2014 | 6 Pages |
Abstract
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (PÂ <Â 0.0001) and 1.7 times higher than in ET (PÂ =Â 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Elisabeth Ejerblad, Sonja Zweegman, Savio Fernandes, David Bareford, Steven Knapper, Eva Löfvenberg, Olle Linder, Bjørn Andreasson, Erik Ahlstrand,